These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

705 related articles for article (PubMed ID: 7522954)

  • 41. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
    McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM
    Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959
    [TBL] [Abstract][Full Text] [Related]  

  • 42. TNF alpha enhancement of NK and LAK cell functions induced by high-dose IL-2 in human peripheral blood mononuclear cells from patients pretreated with alpha IFN + IL-2.
    Favrot M; Combaret V; Blay JY; Capdeville R; Zhou DC; Clapisson G; Chouaib S; Franks CR; Philip T
    Eur Cytokine Netw; 1990; 1(4):221-7. PubMed ID: 2104243
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Natural killer cell cytotoxicity is enhanced by very low doses of rIL-2 and rIFN-alpha in patients with renal cell carcinoma.
    Pavone L; Fanti G; Bongiovanni C; Goldoni M; Alberici F; Bonomini S; Cristinelli L; Buzio C
    Med Oncol; 2009; 26(1):38-44. PubMed ID: 18516705
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bone marrow and peripheral blood natural killer cell activity in lymphomas. Its response to IL-2.
    Caldera LH; Leon-Ponte M; Acquatella G; Bianco NE; Blanca I
    Clin Exp Immunol; 1992 Apr; 88(1):143-8. PubMed ID: 1373350
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A pilot study of intralymphatic interleukin-2. I. Cytotoxic and surface marker changes of peripheral blood lymphocytes.
    Shau H; Isacescu V; Ibayashi Y; Tokuda Y; Golub SH; Fahey JL; Sarna GP
    J Biol Response Mod; 1990 Feb; 9(1):71-80. PubMed ID: 2319261
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Down-regulation of KOLT-2 antigen (CD28) by interleukin 2; role of IL-2R (p70).
    Shindo T; Sugie K; Nakamura K; Tagaya Y; Maeda M; Uchiyama T; Sagawa K; Yokoyama M; Wada H; Hitomi S
    Immunology; 1990 Sep; 71(1):63-9. PubMed ID: 2170270
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term treatment with low doses of interleukin-2 and interferon-alpha: immunological effects in advanced renal cell cancer.
    Pavone L; Andrulli S; Santi R; Majori M; Buzio C
    Cancer Immunol Immunother; 2001 Apr; 50(2):82-6. PubMed ID: 11401029
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impaired natural killer activity and expression of interleukin-2 receptor antigen in familial erythrophagocytic lymphohistiocytosis.
    Kataoka Y; Todo S; Morioka Y; Sugie K; Nakamura Y; Yodoi J; Imashuku S
    Cancer; 1990 May; 65(9):1937-41. PubMed ID: 2372765
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Receptor-specific inhibition of bone marrow erythropoiesis by recombinant DNA-derived interleukin-2.
    Burdach SE; Levitt LJ
    Blood; 1987 May; 69(5):1368-75. PubMed ID: 3105620
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Different sensitivity to interleukin 4 of interleukin 2- and interferon alpha-induced CD69 antigen expression in human resting NK cells and CD3+, CD4-, CD8- lymphocytes.
    Gerosa F; Tommasi M; Carra G; Gandini G; Tridente G; Benati C
    Cell Immunol; 1992 May; 141(2):342-51. PubMed ID: 1533569
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Activation of natural killer cells via the p75 interleukin 2 receptor.
    Phillips JH; Takeshita T; Sugamura K; Lanier LL
    J Exp Med; 1989 Jul; 170(1):291-6. PubMed ID: 2787381
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interleukin-2- and mitogen-activated NK-like killer cells from highly purified human peripheral blood T cell (CD3+ N901-) cultures.
    Atzpodien J; Wisniewski D; Gulati S; Welte K; Knowles R; Clarkson B
    Nat Immun Cell Growth Regul; 1987; 6(3):129-40. PubMed ID: 3114621
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synergistic and antagonistic effects of IL-1 alpha and IL-4, respectively, on the IL-2-dependent growth of a T cell receptor-gamma delta+ human T leukemia cell line.
    Santoli D; O'Connor R; Cesano A; Phillips P; Colt TL; Lange B; Clark SC; Rovera G
    J Immunol; 1990 Jun; 144(12):4703-11. PubMed ID: 2351825
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2.
    Schomburg A; Menzel T; Körfer A; Heer G; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
    Nat Immun; 1992; 11(3):133-43. PubMed ID: 1392401
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interleukin-2 therapy after bone marrow or stem cell transplantation for hematologic malignancies.
    Fefer A; Robinson N; Benyunes MC; Bensinger WI; Press O; Thompson JA; Lindgren C
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S48-53. PubMed ID: 9457394
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bispecific antibody-directed antitumor activity of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus interleukin 2.
    Nishimura T; Nakamura Y; Takeuchi Y; Gao XH; Tokuda Y; Okumura K; Habu S
    Jpn J Cancer Res; 1991 Nov; 82(11):1207-10. PubMed ID: 1836455
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Regulation of human large granular lymphocyte and T cell growth and function by recombinant interleukin 2: induction of interleukin 2 receptor and promotion of growth of cells with enhanced cytotoxicity.
    Yamada S; Ruscetti FW; Overton WR; Herberman RB; Birchenall-Sparks MC; Ortaldo JR
    J Leukoc Biol; 1987 Jun; 41(6):505-17. PubMed ID: 3110337
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation.
    Blaise D; Olive D; Stoppa AM; Viens P; Pourreau C; Lopez M; Attal M; Jasmin C; Monges G; Mawas C
    Blood; 1990 Sep; 76(6):1092-7. PubMed ID: 2400805
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A phase I study of subcutaneous recombinant interleukin-2 in patients with advanced HIV disease while on zidovudine.
    McMahon DK; Armstrong JA; Huang XL; Rinaldo CR; Gupta P; Whiteside TL; Pazin GJ; Tripoli C; Ho M
    AIDS; 1994 Jan; 8(1):59-66. PubMed ID: 8011237
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Activation of peripheral blood T cells via the p75 interleukin 2 receptor.
    Yagita H; Nakata M; Azuma A; Nitta T; Takeshita T; Sugamura K; Okumura K
    J Exp Med; 1989 Oct; 170(4):1445-50. PubMed ID: 2571670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.